Cargando…

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review

Background: Nocebo refers to adverse events related to patients’ negative expectations and previous experiences, mediated by several neurobiological pathways within the brain. It is common among neurological patients and affects adherence and treatment outcomes, representing a real clinical challeng...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spanou, Ioanna, Mavridis, Theodoros, Mitsikostas, Dimos D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667943/ https://www.ncbi.nlm.nih.gov/pubmed/31396084 http://dx.doi.org/10.3389/fphar.2019.00809

Ejemplares similares

Editorial: Nocebo Effects and Their Influence on Clinical Trials and Practice: Modulating Factors in Healthy and Pathological Conditions
por: Amanzio, Martina, et al.
Publicado: (2020)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

EHMTI-0331. Q-No: a questionnaire to predict nocebo in outpatients seeking neurological consultation
por: Deligianni, C, et al.
Publicado: (2014)

Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect
por: Rezk, Mourad F., et al.
Publicado: (2017)

The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies
por: Odinet, Johlee S., et al.
Publicado: (2018)

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

The role of the Nocebo effect in the use of biosimilars in routine rheumatology clinical practice
por: Kravvariti, Evrydiki, et al.
Publicado: (2019)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

The Placebo and Nocebo Responses in Clinical Trials in Inflammatory Bowel Diseases
por: Enck, Paul, et al.
Publicado: (2021)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
por: Huang, Hui-Yao, et al.
Publicado: (2020)

Nocebo Effects on Muscular Performance – An Experimental Study About Clinical Situations
por: Zech, Nina, et al.
Publicado: (2019)

Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
por: Frisaldi, Elisa, et al.
Publicado: (2023)

European Headache Federation recommendations for placebo and nocebo terminology
por: Mitsikostas, Dimos D., et al.
Publicado: (2020)

Nocebo-Prone Behaviour in Patients with Autoimmune Rheumatic Diseases during the COVID-19 Pandemic
por: Fragoulis, George E., et al.
Publicado: (2020)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
por: Mavridis, Theodoros, et al.
Publicado: (2021)

B-Cell Targeted Therapies in Patients with Multiple Sclerosis and Incidence of Headache: A Systematic Review and Meta-Analysis
por: Mavridis, Theodoros, et al.
Publicado: (2022)

The Effect of Television and Print News Stories on the Nocebo Responding Following a Generic Medication Switch
por: MacKrill, Kate, et al.
Publicado: (2020)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

Can Positive Framing Reduce Nocebo Side Effects? Current Evidence and Recommendation for Future Research
por: Barnes, Kirsten, et al.
Publicado: (2019)

Nocebo Effects and Negative Suggestions in Daily Clinical Practice – Forms, Impact and Approaches to Avoid Them
por: Hansen, Ernil, et al.
Publicado: (2019)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers
por: Mitsikostas, Dimos D., et al.
Publicado: (2021)

Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
por: Petit, Juliette, et al.
Publicado: (2021)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
por: Gklinos, Panagiotis, et al.
Publicado: (2020)

Why are biosimilars much more complex than generics?
por: Pagani, Eduardo
Publicado: (2019)

Neuropathic Pain in Neurologic Disorders: A Narrative Review
por: Mitsikostas, Dimos-Dimitrios, et al.
Publicado: (2022)

COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study
por: Fragoulis, George E., et al.
Publicado: (2021)

Placebo – Nocebo
por: Mosser, Astrid
Publicado: (2022)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

A systematic review of sex differences in the placebo and the nocebo effect
por: Vambheim, Sara M, et al.
Publicado: (2017)

Pain Anticipation and Nocebo-Related Responses: A Descriptive Mini-Review of Functional Neuroimaging Studies in Normal Subjects and Precious Hints on Pain Processing in the Context of Neurodegenerative Disorders
por: Amanzio, Martina, et al.
Publicado: (2019)

The Inflation Reduction Act: A boon for the generic and biosimilar industry
por: Niazi, Sarfaraz K.
Publicado: (2022)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Perceptions of generic medication in the general population, doctors and pharmacists: a systematic review
por: Colgan, Sarah, et al.
Publicado: (2015)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease
por: Wu, Guozhi, et al.
Publicado: (2021)

Pharmacovigilance of biosimilars – Why is it different from generics and innovator biologics?
por: Oza, B, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gku2hdvkbf2c104ste6gsvmmsm